PL3455631T3 - Sposoby klasyfikowania pacjentów z nowotworem litym - Google Patents
Sposoby klasyfikowania pacjentów z nowotworem litymInfo
- Publication number
- PL3455631T3 PL3455631T3 PL17725195T PL17725195T PL3455631T3 PL 3455631 T3 PL3455631 T3 PL 3455631T3 PL 17725195 T PL17725195 T PL 17725195T PL 17725195 T PL17725195 T PL 17725195T PL 3455631 T3 PL3455631 T3 PL 3455631T3
- Authority
- PL
- Poland
- Prior art keywords
- methods
- solid cancer
- classifying patients
- classifying
- patients
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 239000007787 solid Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6851—Quantitative amplification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6844—Nucleic acid amplification reactions
- C12Q1/6862—Ligase chain reaction [LCR]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/30—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for calculating health indices; for individual health risk assessment
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/50—Determining the risk of developing a disease
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Molecular Biology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Organic Chemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Cell Biology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Medical Informatics (AREA)
- Public Health (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16305536 | 2016-05-09 | ||
| PCT/EP2017/061089 WO2017194556A1 (en) | 2016-05-09 | 2017-05-09 | Methods for classifying patients with a solid cancer |
| EP17725195.6A EP3455631B1 (en) | 2016-05-09 | 2017-05-09 | Methods for classifying patients with a solid cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL3455631T3 true PL3455631T3 (pl) | 2021-04-06 |
Family
ID=56014938
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL17725195T PL3455631T3 (pl) | 2016-05-09 | 2017-05-09 | Sposoby klasyfikowania pacjentów z nowotworem litym |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20190309369A1 (enExample) |
| EP (1) | EP3455631B1 (enExample) |
| JP (3) | JP7281903B2 (enExample) |
| KR (1) | KR102245021B1 (enExample) |
| CN (2) | CN109690314B (enExample) |
| AU (1) | AU2017261685B2 (enExample) |
| ES (1) | ES2808004T3 (enExample) |
| MX (1) | MX393482B (enExample) |
| PL (1) | PL3455631T3 (enExample) |
| RU (1) | RU2745730C2 (enExample) |
| SG (1) | SG11201809317VA (enExample) |
| WO (1) | WO2017194556A1 (enExample) |
| ZA (1) | ZA201807020B (enExample) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20180357361A1 (en) | 2017-06-13 | 2018-12-13 | Feliks Frenkel | Systems and methods for identifying responders and non-responders to immune checkpoint blockade therapy |
| EP3659110A1 (en) | 2017-07-24 | 2020-06-03 | Ventana Medical Systems, Inc. | Methods and systems for evaluation of immune cell infiltrate in tumor samples |
| DK3746790T3 (da) * | 2018-01-31 | 2023-12-11 | Ventana Med Syst Inc | Fremgangsmåder og systemer til evaluering af immuncelleinfiltrat i kolorektal stadie III cancer |
| FR3079617B1 (fr) | 2018-03-29 | 2023-12-22 | Office National Detude Et De Rech Aerospatiales Onera | Methode de detection de cellules presentant au moins une anomalie dans un echantillon cytologique |
| WO2020245155A1 (en) | 2019-06-03 | 2020-12-10 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for modulating a treatment regimen |
| CN110988324B (zh) * | 2019-11-29 | 2021-08-24 | 广州市雷德医学检验实验室有限公司 | 免疫状态确定系统、方法、装置及存储介质 |
| CN111257563B (zh) * | 2020-01-22 | 2022-08-23 | 广州泛恩生物科技有限公司 | Cxcl13检测剂在制备预测免疫治疗效果的试剂盒中的用途 |
| CN111999503B (zh) * | 2020-05-28 | 2022-05-20 | 首都医科大学附属北京地坛医院 | 一组用于预测急性病毒性呼吸道传染病重症化的标志物及其应用和试剂盒 |
| EP4172628A1 (en) * | 2020-06-30 | 2023-05-03 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery |
| CN113174439B (zh) * | 2021-03-30 | 2022-06-28 | 中国医学科学院肿瘤医院 | 一种基于免疫基因对评分体系在预测非小细胞肺癌患者免疫治疗效果中的应用 |
| US20240210404A1 (en) * | 2021-04-27 | 2024-06-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the risk of lymph node metastasis and/or recurrence of patients suffering from a t1 cancer treated by endoscopic resection |
| KR20220155554A (ko) * | 2021-05-13 | 2022-11-23 | 주식회사 센트릭스바이오 | 항-CD300c 항체를 이용한 병용 요법 |
| CA3245129A1 (en) | 2022-03-17 | 2023-09-21 | Univ Paris Cite | METHODS FOR PREDICTING RESPONSE TO IMMUNOTHERAPEUTIC TREATMENT IN A CANCER PATIENT |
| EP4533092A1 (en) * | 2022-06-03 | 2025-04-09 | Universita'Degli Studi di Roma "La Sapienza" | Method for determining the prognostic score in patients with metastatic renal carcinoma |
| CN115058504B (zh) * | 2022-07-14 | 2025-07-04 | 广州医科大学 | 膀胱癌th17 cd4+t细胞亚群及其特征基因与应用 |
| CN115747331B (zh) * | 2022-09-22 | 2023-08-25 | 中山大学肿瘤防治中心（中山大学附属肿瘤医院、中山大学肿瘤研究所） | 用于预测鼻咽癌预后的三级淋巴结构成分标志物组合、系统及应用 |
| TWI826081B (zh) * | 2022-10-28 | 2023-12-11 | 臺北醫學大學 | 癌症進展評估方法及其系統 |
| CN117476097B (zh) * | 2023-10-25 | 2024-06-07 | 中山大学附属第六医院 | 一种基于三级淋巴结构特征基因的结直肠癌预后和治疗反应预测模型及其构建方法和应用 |
| CN119685476A (zh) * | 2024-05-29 | 2025-03-25 | 深圳湾实验室 | 一种与癌症预后相关的基因标志物及其应用 |
| CN119291200A (zh) * | 2024-10-16 | 2025-01-10 | 华中科技大学同济医学院附属协和医院 | 一种用于检测cxcr4+cd8+t细胞用于预测肿瘤免疫治疗的检测试剂盒 |
| CN120259410B (zh) * | 2025-06-05 | 2025-09-23 | 北京大橡科技有限公司 | 基于双Panel多重生物标志物分析的肿瘤免疫响应可能性的评分方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2006521562A (ja) * | 2003-03-07 | 2006-09-21 | スレショルド ファーマシューティカルズ インコーポレイティッド | 抗悪性腫瘍剤による治療に対する腫瘍の感受性を決定する方法 |
| AR053272A1 (es) * | 2005-05-11 | 2007-04-25 | Hoffmann La Roche | Determinacion de responsivos a la quimioterapia |
| NZ562237A (en) * | 2007-10-05 | 2011-02-25 | Pacific Edge Biotechnology Ltd | Proliferation signature and prognosis for gastrointestinal cancer |
| CA2758531C (en) * | 2009-04-14 | 2018-11-13 | Derren Barken | Inflammatory bowel disease prognostics |
| EP2619576B1 (en) * | 2010-09-24 | 2020-06-10 | Niels Grabe | Means and methods for the prediction of treatment response of a cancer patient |
| GB201021289D0 (en) * | 2010-12-15 | 2011-01-26 | Immatics Biotechnologies Gmbh | Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer |
| EP2805165B1 (en) * | 2012-01-20 | 2018-03-14 | INSERM - Institut National de la Santé et de la Recherche Médicale | Methods for predicting the survival time of a patient suffering from a solid cancer based on density of b cells |
| AU2013276470B2 (en) * | 2012-06-14 | 2018-06-07 | Assistance Publique Hopitaux De Paris | Method for quantifying immune cells in tumoral tissues and its applications |
| US11242564B2 (en) * | 2012-07-12 | 2022-02-08 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods for predicting the survival time and treatment responsiveness of a patient suffering from a solid cancer with a signature of at least 7 genes |
| EP3470531A1 (en) * | 2012-08-06 | 2019-04-17 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and kits for screening patients with a cancer |
| HK1211322A1 (en) * | 2013-03-15 | 2016-05-20 | 昂考梅德药品有限公司 | Methods of treating pancreatic cancer |
| WO2015007625A1 (en) * | 2013-07-15 | 2015-01-22 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method for the prognosis of survival time of a patient suffering from a solid cancer |
-
2017
- 2017-05-09 CN CN201780028301.7A patent/CN109690314B/zh active Active
- 2017-05-09 ES ES17725195T patent/ES2808004T3/es active Active
- 2017-05-09 AU AU2017261685A patent/AU2017261685B2/en active Active
- 2017-05-09 KR KR1020187035300A patent/KR102245021B1/ko active Active
- 2017-05-09 JP JP2018559227A patent/JP7281903B2/ja active Active
- 2017-05-09 EP EP17725195.6A patent/EP3455631B1/en active Active
- 2017-05-09 RU RU2018143409A patent/RU2745730C2/ru active
- 2017-05-09 MX MX2018013744A patent/MX393482B/es unknown
- 2017-05-09 SG SG11201809317VA patent/SG11201809317VA/en unknown
- 2017-05-09 WO PCT/EP2017/061089 patent/WO2017194556A1/en not_active Ceased
- 2017-05-09 CN CN202210976807.3A patent/CN115198018A/zh active Pending
- 2017-05-09 US US16/099,451 patent/US20190309369A1/en active Pending
- 2017-05-09 PL PL17725195T patent/PL3455631T3/pl unknown
-
2018
- 2018-10-22 ZA ZA2018/07020A patent/ZA201807020B/en unknown
-
2021
- 2021-11-19 JP JP2021188647A patent/JP7654318B2/ja active Active
-
2023
- 2023-12-14 JP JP2023211166A patent/JP2024019551A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP7281903B2 (ja) | 2023-05-26 |
| AU2017261685B2 (en) | 2023-09-07 |
| MX2018013744A (es) | 2019-08-16 |
| KR102245021B1 (ko) | 2021-04-26 |
| BR112018072993A8 (pt) | 2022-11-08 |
| EP3455631A1 (en) | 2019-03-20 |
| JP2022027788A (ja) | 2022-02-14 |
| ES2808004T3 (es) | 2021-02-25 |
| RU2018143409A (ru) | 2020-06-10 |
| RU2745730C2 (ru) | 2021-03-31 |
| US20190309369A1 (en) | 2019-10-10 |
| SG11201809317VA (en) | 2018-11-29 |
| BR112018072993A2 (pt) | 2019-03-06 |
| AU2017261685A1 (en) | 2018-11-15 |
| WO2017194556A1 (en) | 2017-11-16 |
| EP3455631B1 (en) | 2020-06-24 |
| JP7654318B2 (ja) | 2025-04-01 |
| MX393482B (es) | 2025-03-24 |
| CN115198018A (zh) | 2022-10-18 |
| CN109690314A (zh) | 2019-04-26 |
| ZA201807020B (en) | 2020-05-27 |
| RU2018143409A3 (enExample) | 2020-06-29 |
| KR20190016025A (ko) | 2019-02-15 |
| JP2019516979A (ja) | 2019-06-20 |
| JP2024019551A (ja) | 2024-02-09 |
| CN109690314B (zh) | 2022-08-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201807020B (en) | Methods for classifying patients with a solid cancer | |
| ZA201702382B (en) | Combination therapy for cancer | |
| HUE059484T2 (hu) | Az NY-ESO-1 tumorantigén - HLA-A | |
| EP3226763A4 (en) | Imaging a body | |
| EP3177225A4 (en) | Stereotactic template | |
| GB201420859D0 (en) | Tumour analysis | |
| GB2551892B (en) | Cancer treatment - proton tomography apparatus | |
| IL249898A0 (en) | Combined cancer treatment | |
| GB201611173D0 (en) | Inductive detector | |
| GB201500584D0 (en) | Cancer biomarkers | |
| IL246761A0 (en) | Combined cancer treatment | |
| IL277752A (en) | Cancer vaccines | |
| PL3487632T3 (pl) | Urządzenie klasyfikujące | |
| GB2552271B (en) | A method for diagnosing lung cancer | |
| GB201407755D0 (en) | Nanocrystals | |
| GB2546773B (en) | Cancer | |
| GB201508480D0 (en) | Cancer | |
| SG11201610119TA (en) | A diagnostic and therapeutic tool for cancer | |
| GB2542843B (en) | Inductive position detector | |
| GB201604813D0 (en) | Methods for detecting cancer | |
| GB201611167D0 (en) | Inductive detector | |
| AP2016009066A0 (en) | A drug for treating cancer | |
| GB201508117D0 (en) | A cancer therapy | |
| GB201405286D0 (en) | Cancer diagnostic | |
| GB201409311D0 (en) | Colorectal cancer |